COMMUNIQUÉS West-GlobeNewswire

-
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025 -
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025 -
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025 -
Children’s National ranked top hospital in the nation by U.S. News & World Report
07/10/2025 -
Scottish Rite for Children Ranked No. 1 for Pediatric Orthopedic Care by U.S. News & World Report
07/10/2025 -
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
07/10/2025 -
Carlsbad Dental Care Expands Access to Modern Dentistry with New Patient Special and Financing Options
07/10/2025 -
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025 -
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025 -
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025 -
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025 -
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025 -
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025 -
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
07/10/2025 -
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
07/10/2025 -
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
07/10/2025 -
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
07/10/2025 -
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
06/10/2025 -
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
06/10/2025
Pages